MBMark Baron

Mark Baron

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Mark Baron has a total of 16 co-authors. Here are the top co-authors by number of shared publications:

  • Marshall Devor

    Department of Cell and Developmental Biology, Institute of Life Sciences, The Hebrew University of Jerusalem, Jerusalem, Israel

    8 shared publications
  • Anne Minert

    Department of Cell and Developmental Biology, Silberman Institute of Life Sciences, The Hebrew University of Jerusalem, Safra Givat Ram Campus, Jerusalem 9190401, Israel

    3 shared publications
  • Marshall Devor

    Institute of Life Sciences, The Hebrew University of Jerusalem, Jerusalem 9190401, Israel; Center for Research on Pain, The Hebrew University of Jerusalem, Jerusalem 9190401, Israel

    3 shared publications
  • Kristina Vaso

    Department of Cell and Developmental Biology, Silberman Institute of Life Sciences, The Hebrew University of Jerusalem, Safra Givat Ram Campus, Jerusalem 9190401, Israel

    2 shared publications
  • Mary Koukoui

    Department of Cell and Developmental Biology, Silberman Institute of Life Sciences, The Hebrew University of Jerusalem, Safra Givat Ram Campus, Jerusalem 9190401, Israel

    2 shared publications
  • Angham Ibraheem

    Department of Cell and Developmental Biology, Institute of Life Sciences, The Hebrew University of Jerusalem, Jerusalem, Israel

    1 shared publication

Latest Publications

  • Open Access

    Axonal Projections of Neurons in the Brainstem Mesopontine Tegmental Anesthesia Area (MPTA) That Effect Anesthesia, Enabling Pain-Free Surgery

    by Juliet Miller, Anne Minert, Mary Koukoui, Shaked Heller, Roza Morein, Mark Baron, Kristina Vaso, Marshall Devor

    Background/Objectives: Chemogenetic excitation of a distinct subset of “effector-neurons” in the brainstem mesopontine tegmental anesthesia area (MPTA) is pro-anesthetic. GABAergic general anesthetics are believed to engage these neurons by disinhibition, thereby inducing loss-of-consciousness (LOC) and enabling pain-free surgery. The transition from wakefulness to LOC, however, does not occur intrinsically within the MPTA. Rather, evidence indicates that LOC is brought about (effected) by ascending and descending axonal projections of MPTA effector-neurons that terminate in a variety of downstream brain targets which, together, generate the various components of anesthesia. Previously we used anterograde and retrograde tracing to delineate the overall axonal trajectories of MPTA projection-neurons, to which targets they project. Effector-neurons, however, represent only a fraction of this neuronal pool. Which of these targets are also innervated by MPTA projecting effector-neurons? Methods: Here we marked MPTA effector-neurons with the adeno-associated virus (AAV) used in the discovery of this neuronal type, with retrograde labelling from the previously identified MPTA target structures, to establish which downstream brain structures receive direct input from effector-neurons. Results: Effector-neurons proved to contribute to all six of the major MPTA projection-targets: the prefrontal cortex, basal forebrain, intralaminar thalamus, zona incerta, rostro-ventromedial medulla and spinal cord. Conclusions: We conclude that a discrete population of projecting effector-neurons, probably representing only about 6% of all MPTA neurons, drive the multiple functional endpoints of surgical anesthesia: analgesia, atonia, amnesia and LOC. Further, we propose that these same neurons, via their associated axonal pathways, may also contribute to endogenous instances of LOC such as natural sleep, fainting, concussion, coma and hibernation.


  • Pain and the evolutionary origins of subjective experience

    by Mark Baron, Anne Minert, Marshall Devor

    The cerebral neocortex is essential for the complex feature extractions underlying sensory perception. Pain is an exception. Its adaptive message, fight or flee, is already available at the first central synapse. We propose that raw consciousness emerged with pain. Eons later the cortical supercomputer began providing complex computational output to the primeval circuitry of conscious pain experience, already operating subcortically.


  • Open Access

    Molecular and cellular targets of GABAergic anesthetics in the mesopontine tegmentum that enable pain-free surgery

    by Mark Baron, Kristina Vaso, Angham Ibraheem, Anne Minert, Marshall Devor

    The mesopontine tegmental anesthesia area (MPTA) is a focal brainstem locus which, when exposed to GABAergic agents, induces brain-state transitioning from wakefulness to unconsciousness. Correspondingly, MPTA lesions render animals relatively insensitive to GABAergic anesthetics delivered systemically. Using chemogenetics, we recently identified a neuronal subpopulation within the MPTA whose excitation induces this same pro-anesthetic effect. However, very few of these “effector-neurons” express synaptic γ 2-containing GABAA receptor isoforms and none express extrasynaptic δ-subunit containing receptors, suggesting that they are not the direct cellular target of GABAergic agents. Here we used pharmacological tools in rats to define the molecular target(s) of GABAergics in the MPTA. GABA microinjected into the MPTA at nanomolar concentrations, selective for GABAA δ-Rs, proved to be pro-anesthetic as was blocking GABA reuptake. Likewise, low-concentration gaboxadol/THIP, also selective for GABAA δ-Rs, was effective, whereas benzodiazepines and zolpidem, which selectively target GABAA γ 2-Rs, were not. The GABAergic anesthetics pentobarbital and propofol proved pro-anesthetic when applied to the MPTA at the low concentrations present in the brain after systemic dosing. Glycinergic agonists which are inhibitory, but infective on GABAA δ-Rs, and other non-GABAergic agonists tested, were at most only marginally effective. We conclude that GABAA δ-Rs are the primary molecular target of GABAergic anesthetics in the MPTA. Immunolabeling revealed that this GABAA-R isoform is expressed exclusively by a distinct subpopulation of MPTA “δ-cells” that reside in close apposition to effector neurons. This suggests that during wakefulness, δ-cells serve as inhibitory interneurons which, when silenced by GABAergic agents, disinhibit (excite) the effector-neurons, triggering transition to unconsciousness.


  • Faculty Opinions recommendation of Gate control of sensory neurotransmission in peripheral ganglia by proprioceptive sensory neurons.

    by Marshall Devor, Mark Baron

    Signal processing within DRGs The authors argue that parvalbumin-expressing primary sensory neurons (PV+ neurons) in the mouse dorsal root ganglion (DRG) gate the flow of noxious signals into the CNS in a manner analogous to that of the famous Gate Control theory of pain. The proposed mechanism is release of a neurotransmitter within the ganglion, rather than synaptic action in the dorsal horn. The released neurotransmitter excites nociceptors via a non-synaptic, apparently paracrine action. This is out-of-the-box thinking. Cell somata in the DRG are generally considered to be no more than metabolic factories tasked with maintaining their huge axons. They are not often thought of as significant contributors to sensory signal processing. The principal evidence given is that genetic ablation of most (~2/3) of the PV+ neurons in the L4DRG increases discharge rates of the residual (~1/3) PV+ neurons, recorded optically in anesthetized animals using GCaMP. This includes ongoing discharge and responsiveness to a variety of mechanical, thermal and chemical stimuli applied to the hindpaw skin. It also renders the mice behaviourally hypersensitive to the corresponding stimuli in the awake state. The authors are noncommittal about how this intra-ganglionic excitation works. One idea, based on observations of Gamper's group (Du et al. 2017 {1}), is that baseline discharge causes DRG cells to release GABA in the ganglion, thus inhibiting spike activity generated ectopically and suppressing pain behaviour. Ablating 2/3 of the GABAergic PV+ neurons might reduce this background GABAegic inhibition, thus exciting the residual 1/3 of PV+ neurons by disinhibition. Another idea was co-release of (excitatory) glutamate, along with GABA, from the PV+ neurons. Several minor caveats should be mentioned. For example: 1) the PV+ neurons recorded from are referred to as "proprioceptors", afferents that monitor joint angle and muscle contraction. But their receptive fields, and the stimuli applied to generate the enhanced discharge, were cutaneous and nociceptive. 2) Changing the membrane potential of DRG somata alters discharge originating from within the DRG, as Du et al. and many others have shown. But the response to stimulation at the sensory ending should not be affected (e.g. Amir & Devor 2003 {2}). 3) Moreover, our group failed to see inhibitory effects of GABA on ectopic discharge originating in DRG neurons (Koplovitch et al. 2018 {3}). 4) Partial nerve injury, the key manipulation used here, is an aspect of many rodent neuropathic pain models. A good deal of evidence based on these models suggests that the mechanism of hypersensitivity is primarily spinal, the same sort of modulation incorporated in the Gate Control theory, and not an exotic intra-ganglionic process. Be that as it may, intra-ganglionic signal processing is a good idea. Despite the fact that DRG afferents are among the most closely studied of all neurons in the nervous system, they exhibit a variety of peculiarities which remain mysterious to this day (Devor 1999 {4}). These include expression of numerous membranal synaptic receptors by DRG cell somata, and the release of neurotransmitters, despite the fact that virtually no synapses occur in DRGs. The suggestion that DRGs process and modify sensory signals, perhaps employing paracrine signalling, is intriguing and deserves continued research investment.

  • Open Access

    From molecule to oblivion: dedicated brain circuitry underlies anesthetic loss of consciousness permitting pain-free surgery

    by Mark Baron, Marshall Devor

    The canonical view of how general anesthetics induce loss-of-consciousness (LOC) permitting pain-free surgery posits that anesthetic molecules, distributed throughout the CNS, suppress neural activity globally to levels at which the cerebral cortex can no longer sustain conscious experience. We support an alternative view that LOC, in the context of GABAergic anesthesia at least, results from anesthetic exposure of a small number of neurons in a focal brainstem nucleus, the mesopontine tegmental anesthesia area (MPTA). The various sub-components of anesthesia, in turn, are effected in distant locations, driven by dedicated axonal pathways. This proposal is based on the observations that microinjection of infinitesimal amounts of GABAergic agents into the MPTA, and only there, rapidly induces LOC, and that lesioning the MPTA renders animals relatively insensitive to these agents delivered systemically. Recently, using chemogenetics, we identified a subpopulation of MPTA “effector-neurons” which, when excited (not inhibited), induce anesthesia. These neurons contribute to well-defined ascending and descending axonal pathways each of which accesses a target region associated with a key anesthetic endpoint: atonia, anti-nociception, amnesia and LOC (by electroencephalographic criteria). Interestingly, the effector-neurons do not themselves express GABAA-receptors. Rather, the target receptors reside on a separate sub-population of presumed inhibitory interneurons. These are thought to excite the effectors by disinhibition, thus triggering anesthetic LOC.


  • Faculty Opinions recommendation of Neuropathic pain caused by miswiring and abnormal end organ targeting.

    by Marshall Devor, Mark Baron

    A common sequel of nerve injury is pain evoked by gentle touch in nearby skin denervated as a result of the injury. Kuner's group tracked the growth of fine unmyelinated and lightly myelinated nociceptive axons into such an area in the hindpaw in mice, and in parallel mapped axonal receptive fields and behavioral responses to applied stimuli. The results suggested a novel pain mechanism; that collateral sprouts are induced to grow out from nociceptive axons of intact neighboring nerves that were not themselves injured. These invade and re-innervated the previously denervated skin. However, unlike normal C- and A-delta nociceptors that need strong, usually pain-provoking stimuli to be activated, the sensory endings of the collateral sprouts are abnormally sensitive. For this reason, light touch on the re-innervated skin is felt as painful… "tactile allodynia". The authors brought a remarkable array of gene-based biological technologies and advanced optical and computational resources to bear on the difficult problem of imaging specific populations of cutaneous afferent axons in vivo, and in some experiments selectively ablating them. Nocifensive responses to the application of fine von Frey filaments were used to behaviorally monitor the advancing front of allodynia, and the in vitro skin-nerve preparation (skin excised with nerves attached) was used to record responses of single cutaneous axons to the same applied von Frey stimuli. Collateral sprouting is not itself a new discovery. Innervation territories of neighboring nerves tend to overlap without sharp boundaries between them, and it has long been appreciated, in animals and man, that when a nerve is cut across axons, adjacent nerves invade the denervated (or partly denervated) territory. The attraction signal is probably nerve growth factor (NGF) and/or other molecules released into the tissue during the process of Wallerian degeneration of distal nerve elements now disconnected from their proximal nutrient source, the nerve cell soma in the dorsal root ganglion. Interestingly, if the cut nerve is able to regenerate, its outgrowing processes tend to push invading collateral sprouts back towards their original borders, in a sort of chemical warfare {1,2}. Such competition between terminal arbor fields is probably a dynamic process in healthy tissues, a process that serves to maintain normal axon collateralization. There are, however, some caveats and question marks that need to be considered. For example, it took up to a week for the supposedly denervated skin of toe #3 to lose response to noxious mechanical stimulation. This should have occurred instantly. Could there have been some residual sensory innervation not visualized by the novel method used? In the spared nerve injury (SNI) model used here, there are actually two hindpaw nerves spared: the sural nerve serving the skin of the lateral toes and paw, discussed in detail, and the saphenous nerve serving the medial toes and paw, not mentioned and presumably not seen in the multi-photon images. In the SNI model, the spared sural and saphenous nerves together provide nociceptive sensory cover, preventing autotomy (self-mutilation) of otherwise numb toes. This is one of SNI's key advantages {3,4}. The timing of sensory changes is also curious. Using the SNI model, allodynia in rats and mice usually emerges in 3-4 days, reaching a stable maximum within a week {5}. Here, on toe #3, at least, it took 20 weeks. Finally, allodynia in nerve-injured patients is felt instantaneously upon touching affected skin (think of touching a patch of sunburn). At C-fiber conduction velocity (≤1m/sec), a delay of 1-2 sec is expected between stimulus and sensation, more if the allodynia is on the foot. The usual explanation is that the painful afferent signal is carried centrally along fast-conducting A-beta axons {6}. The sensation of pain rather than touch is thought to be due to central sensitization ("A-beta pain"). In the mouse skin-nerve preparation used to record receptive fields, it is difficult to distinguish A-beta- from C-fibers on the basis of conduction velocity because of the short distances involved and because collateral sprouts of A-beta axons are likely to be unmyelinated over much of their course. Only axons in the sural nerve were sampled, and recordings did not include toe #3 where the imaging was done. Despite these issues, it is rare for functional changes in experimental neuropathy models to be tracked for nearly a year. The investment in this study appears to have uncovered a novel, late-emerging phenomenon that may well have considerable significance for pain patients, in whom changes that emerge a year down the road are very much relevant.

  • Anesthetic loss of consciousness induced by chemogenetic excitation of mesopontine effector neurons.

    by Mark Baron, Kristina Vaso, Tamir Avigdor, Yelena Charit, Anne Minert, Marshall Devor


  • Searching in the wrong place: Might consciousness reside in the brainstem?

    by Marshall Devor, Mary Koukoui, Mark Baron

    Doubtless, the conscious brain integrates masses of information. But declaring that consciousness simply “emerges” when enough has accumulated, doesn't really explain how first person experience is implemented by neurons. Moreover, empirical observations challenge integrated information theory's (IIT) reliance on thalamo–cortical interactions as the information integrator. More likely, the cortex streams processed information to a still-enigmatic consciousness generator, one perhaps located in the brainstem.